Compare Ascendis Pharma A/S (ASND) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs NIO Inc. — how do they compare? Ascendis Pharma A/S trades at $263.91 (market cap $17.74B), while NIO Inc. trades at $4.92 (market cap $12.35B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | NIO | |
|---|---|---|
Market Cap | $17.74B | $12.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $7.89 |
52-Week Low | $163.32 | $3.90 |
Enterprise Value | $18.11B | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NIO trades at $4.78, unchanged on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but net losses persist at -$15.57B, though margins improved. Vehicle deliveries surged 62.9% year-over-year in June 2026, driven by strong ES9 performance. Cash flow remains negative, with a net cash outflow of -$10.87B in 2024.
The outlook is mixed: robust delivery growth and narrowing losses signal operational progress, but persistent cash burn and high debt pose risks. Analyst consensus leans bullish with 50% buy ratings, yet the stock faces headwinds from competitive pressures and macroeconomic concerns affecting Chinese EV stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
